Comparison of the cost-effectiveness of upfront letrozole or anastrozole, or switched exemestane versus tamoxifen for early breast cancer in hormone receptor positive (HR+) postmenopausal women: the UK perspective

被引：0

作者：

Di Trapani, F. ^{[1
]}

Karnon, J. ^{[2
]}

Kaura, S. ^{[3
]}

机构：

[1] Novartis Pharmaceut, Global Med Affairs Oncol, E Hanover, NJ USA

[2] Univ Sheffield, Sheffield, S Yorkshire, England

[3] Novartis Pharmaceut, E Hanover, NJ USA

来源：

EJC SUPPLEMENTS | 2007年 / 5卷 / 04期

关键词：

D O I：

10.1016/S1359-6349(07)70824-8

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2062

引用

页码：202 / 203

页数：2

共 50 条

[1] Comparison of the cost-effectiveness of upfront letrozole or anastrozole, or switched exemestane versus tamoxifen for early breast cancer in hormone receptor positive (HR+) postmenopausal women: the UK perspective.
Karnon, J.
Delea, T. E.
Kaura Meng, S.
di Trapani, F.
[J]. BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S229 - S229
[2] Comparison of the cost-effectiveness of letrozole or anastrozole versus tamoxifen as adjuvant therapies for early breast cancer in hormone receptor positive (HR+) postmenopausal women: The UK perspective
Karnon, Jonathan
Delea, Thomas
Papo, Natalie L.
Barghout, Victoria
[J]. ANNALS OF ONCOLOGY, 2006, 17 : 107 - 107
[3] Comparison of the cost per distant disease free year gained of upfront letrozole or anastrozole, or switched exemestane versus tamoxifen for early breast cancer in hormone receptor positive (HR+) postmenopausal women: the UK perspective
Karnon, J.
Kaura, S.
di Trapani, F.
[J]. BREAST, 2007, 16 : S64 - S64
[4] Comparison of the cost-effectiveness of upfront letrozole or anastrozole versus tamoxifen for early breast cancer in hormone receptor positive (HR plus ) postmenopausal women the Cypriot perspective
Andreopoulos, D.
Karnon, J.
Kaura, S.
[J]. EJC SUPPLEMENTS, 2008, 6 (07): : 126 - 127
[5] Comparison of cost-effectiveness of aromatase inhibitors letrozole, anastrozole or exemestane versus tamoxifen for early breast cancer in hormone receptor-positive postmenopausal women: Canadian perspective
El Ouagari, K.
Kamon, J.
Kaura, S.
[J]. EJC SUPPLEMENTS, 2007, 5 (04): : 210 - 211
[6] Comparison of the cost per distant disease-free year gained for upfront letrozole or anastrozole, or switched exemestane compared to tamoxifen for early breast cancer in hormone receptor-positive postmenopausal women: The UK perspective
Karnon, J.
di Trapani, F.
Kaura, S.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[7] Cost-effectiveness analysis of anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with hormone receptor-positive (HR+) advanced breast cancer (ABC): a UK perspective
Simons, R
Bassi, R
Jones, D
Barrett-Lee, P
[J]. EUROPEAN JOURNAL OF CANCER, 2002, 38 : S68 - S68
[8] Cost-effectiveness analysis of letrozole versus tamoxifen as initial adjuvant therapy in hormone-receptor positive postmenopausal women with early breast cancer: the UK perspective
Karnon, J
Delea, TE
Barghout, V
Thomas, SK
Papo, NL
Johnston, SRD
[J]. BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S104 - S104
[9] Reflecting time dependency in hazard rates to analyse the cost-effectiveness of letrozole or anastrozole versus tamoxifen as adjuvant therapies for early breast cancer in hormone receptor-positive (HR+) postmenopausal women: The U.S. perspective
Karnon, J.
Mody-Patel, N.
Kaura, S.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[10] Cost-effectiveness analysis of letrozole versus tamoxifen as initial adjuvant therapy in hormone-receptor positive postmenopausal women with early breast cancer in the UK
Karnon, J
Delea, TE
Papo, NL
Barghout, V
Thomas, SK
Johnston, SR
[J]. VALUE IN HEALTH, 2005, 8 (06) : A43 - A43

← 1 2 3 4 5 →